BPC-157
COA published
A synthetic pentadecapeptide studied in in-vitro models of tissue-repair signalling and cellular migration.
From$54.00Select size
BPC-157 + TB-500 Blend
MEASURED PURITY99.54%
A combined preparation of BPC-157 and TB-500 used in comparative tissue-repair research models.
- Test methods
- HPLC-UV + LC-MS
- Purity target
- 99%+ verified
- Sizes available
- 3
- Availability
- In stock
Select size
Quantity
1
Total
$90.00
That's the price. No inflated list, no permanent “discount” code to make it look cheaper than it is.
Batch WB-29053 · Certificate of Analysis available
For Research Use Only. Not for Human Consumption.
Products supplied by Synthrex Biotech LLC are intended strictly for in-vitro laboratory research and development by qualified professionals. They are not drugs, foods, cosmetics, or dietary supplements, and are not approved by the FDA for human or veterinary use. They are not sold for, and must not be used for, human or animal consumption or administration of any kind. Synthrex Biotech LLC is not a compounding pharmacy or chemical compounding facility as defined under section 503A of the Federal Food, Drug, and Cosmetic Act, and is not an outsourcing facility as defined under section 503B of that Act. By purchasing, you affirm that you are a qualified researcher acquiring these materials for lawful research purposes only. A Safety Data Sheet (SDS/MSDS) is available on request for every compound.
Sold by Synthrex Biotech LLC. A Safety Data Sheet (SDS) is available on request at support@synthrexbiotech.com.
✦ Research Notes
Background & literature
Origin
This is not a distinct molecule with a discovery history of its own. It is a co-formulation of two separately characterised peptides — the gastric pentadecapeptide BPC-157, isolated at the University of Zagreb and described in synthetic form in 1993, and TB-500, a synthetic fragment of thymosin beta-4, whose parent protein was sequenced from bovine thymus in 1981. Each has its own literature; the combination does not.
What has been characterised
The two constituents are characterised separately and by different mechanisms: BPC-157 through angiogenic and nitric-oxide signalling in rodent and cell-culture models, thymosin beta-4 through G-actin sequestration and cytoskeletal dynamics in vitro. No peer-reviewed literature characterises this specific co-formulation as a single entity, and no published work establishes an interaction between them. Anything said about the blend is inference from the two component literatures, not a finding about the blend. Neither constituent is FDA-approved for human use, and thymosin beta-4 appears on the WADA Prohibited List. See the individual BPC-157 and TB-500 entries for the primary sources.
Sources
These notes are provided for scientific context only. They describe published laboratory and preclinical research and are not a claim of any effect in humans. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Batch releases & restocks
Know when the next batch is tested
We publish an independent certificate for every lot before it ships. Join the Lab List and we'll tell you when a new one lands and when a sold-out compound is back — plus 15% off your first order, shown on screen the second you join.
Batch and restock notices from Synthrex Biotech LLC. No dosing advice, ever. One-click unsubscribe on every email.
Related Compounds
TB-500
COA published
A thymosin beta-4 fragment investigated in research on cellular migration and angiogenesis pathways.
$50.00View
GLOW Blend
A combined BPC-157, GHK-Cu and TB-500 preparation studied in dermal and repair research contexts.
From$89.00Select size
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.